Loading organizations...
§ Private Profile · Durham, NC, USA
Biotech company developing novel oral inhibitors for prostate and hormonally-driven cancers, focused on oncology treatments.
Innocrin Pharmaceuticals, based in Research Triangle Park, North Carolina, USA, develops novel oral inhibitors targeting prostate and hormonally-driven cancers, focusing on mid-stage oncology treatments. The company has been involved in a $28 million investment group and was part of a $60 million venture round. Key investors include Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, and Astellas Venture Management. Its pipeline includes therapies like VT-464, a dual lyase-selective CYP-17 inhibitor and androgen receptor antagonist for prostate cancer. Innocrin was spun out from Viamet Pharmaceuticals, with leadership including CEO William Moore and founder Fred Eshelman, who also served as Chairman and CEO. The organization was founded in 2004 by Fred Eshelman. The firm focuses on oncology, targets pharmaceutical and healthcare markets.
Innocrin Pharmaceuticals has raised $28.0M across 1 funding round.
Innocrin Pharmaceuticals has raised $28.0M in total across 1 funding round.
Innocrin Pharmaceuticals has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series D in April 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 14, 2015 | $28M Series D | Fred Eshelman | A&B Equity Holdings, Hatteras Venture Partners, Intersouth Partners, Lilly Ventures, Novartis | Announced |
Innocrin Pharmaceuticals has raised $28.0M in total across 1 funding round.
Innocrin Pharmaceuticals's investors include Fred Eshelman, A&B Equity Holdings, Hatteras Venture Partners, Intersouth Partners, Lilly Ventures, Novartis.